Skip to content

Study on the efficacy and cognitive function of magnetic shock therapy on major depressive disorder in adolescents

Study on the efficacy and cognitive function of magnetic shock therapy on major depressive disorder in adolescents

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097437
Enrollment
Unknown
Registered
2025-02-19
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder

Interventions

Intervention group and control group:Magnetic shock therapy combined with conventional medical therapy
Control group:Conventional drug therapy

Sponsors

the first hospital of hebei medical university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Hospitalized patients diagnosed by more than or equal to 2 specialists with intermediate or higher professional titles, who meet the DSM-5 diagnostic criteria for major depressive disorder; 2. Age between 13-18 years old, male or female not limited; 3. Medication selection: relatively stable SSRI drugs within the therapeutic dose range, (right) zopiclone; 4. The informed consent form shall be signed by the patient's legal guardian.

Exclusion criteria

Exclusion criteria: 1Diseases that cause increased intracranial pressure: encephalitis, brain tumors, and cerebral aneurysms; 2Presence of cognitive impairment such as neurodevelopmental disorders or secondary dementia; 3Comorbid other psychiatric disorders; 4Those who are allergic to anesthetics and muscle relaxants; 5Physiotherapy such as MECT and/or repeated transcranial magnetic stimulation within the past 1 month; 6There is a metal implant in the skull and a metal substance in or near the head that cannot be removed; 7Presence of substance dependence or abuse.

Design outcomes

Primary

MeasureTime frame
Improvement in depressive symptoms;

Secondary

MeasureTime frame
The impact on cognitive function.;

Countries

China

Contacts

Public ContactGao Minglong

the first hospital of hebei medical university

liuyanan_66lin@163.com+86 18633889150

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026